PSMA-lutetium radioligand therapy

PSMA-targeted radioligand therapy (e.g., lutetium-177-PSMA)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PSMA-lutetium radioligand therapy, covering 2023-07-28 to 2023-07-28. Get the full timeline:

Most recent: Clinical Trial Update: PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) [Phase 1, Phase 2]